GlassScriptPhysician profile
Shane Michael Dignan
NPI 1679195176
$22,681.40
in general payments reported to CMS, 2019-2025
38 companies · $7,202 in 2025
The $7,202 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,113 · 2022: $2,271 · 2023: $6,199 · 2024: $5,896 · 2025: $7,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19K · Education: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19,065.55 |
| Education | $231.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,690.33 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,955.37 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $1,905.58 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $1,809.56 | 2022-2025 | Invega Sustenna, Spravato, Invega |
| Neurocrine Biosciences, INC. | $1,561.45 | 2021-2025 | Ingrezza |
| Corium, LLC | $1,557.06 | 2022-2025 | Azstarys |
| Abbvie INC. | $1,535.13 | 2021-2025 | |
| Alkermes, INC. | $1,051.83 | 2021-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $986.72 | 2021-2025 | Fanapt, Hetlioz |
| Tris Pharma INC | $887.56 | 2022-2025 | Dyanavel Xr |
| Lundbeck LLC | $865.17 | 2021-2025 | Rexulti, Vyepti |
| Axsome Therapeutics, INC. | $635.68 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $559.39 | 2021-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $466.83 | 2022-2025 | Qelbree, Qelbree |
| Almatica Pharma LLC | $462.05 | 2023-2025 | Loreev Xr |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $451.81 | 2023-2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $343.44 | 2025 | Jornay Pm |
| Validus Pharmaceuticals LLC | $313.15 | 2023-2025 | Equetro, Raldesy, Equetro |
| Ironshore Pharmaceuticals INC. | $306.40 | 2024 | |
| Bausch Health US, LLC | $301.36 | 2021-2025 | Aplenzin, Wellbutrin |
| E.R. Squibb & Sons, L.L.C. | $297.34 | 2025 | Cobenfy |
| Sage Therapeutics, LLC | $294.47 | 2024-2025 | Zurzuvae |
| Indivior INC. | $272.92 | 2023-2024 | Perseris, Sublocade |
| Sunovion Pharmaceuticals INC. | $222.92 | 2021-2022 | |
| Luye Pharma (USA) LTD. | $144.07 | 2025 | Erzofri Extended-Release |
| Avanir Pharmaceuticals, INC. | $112.86 | 2021-2022 | |
| Neos Therapeutics, LP | $88.55 | 2024-2025 | Adzenys Xr-Odt |
| Lilly USA, LLC | $78.65 | 2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $75.41 | 2024-2025 | Wegovy |
| Brainsway USA INC | $73.40 | 2025 | Deep Tms |
| Owp Pharmaceuticals, INC. | $68.69 | 2023-2025 | Subvenite, Lamotrigine |
| Noven Therapeutics, LLC | $61.48 | 2024 | Xelstrym |
| Eisai INC. | $58.91 | 2021 | |
| Merck Sharp & Dohme LLC | $58.69 | 2022-2023 | Belsomra |
| Bioxcel Therapeutics, INC. | $56.91 | 2023 | Igalmi |
| Neuronetics, INC. | $32.37 | 2023 | Neurostar Tms Therapy System |
| Janssen Biotech, INC. | $22.19 | 2023 | |
| Jazz Pharmaceuticals INC. | $15.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Dignan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.